Login to Your Account

Idenix Drops Novartis Deal; Enters All-Oral HCV Race

By Marie Powers
Staff Writer

Wednesday, August 1, 2012
Idenix Pharmaceuticals Inc. boldly joined the growing movement to reconfigure the hepatitis C virus (HCV) market by terminating its 2003 HCV development and commercialization agreement with Novartis AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription